...executive director of the Clinical Trials Transformation Initiative (CTTI), a public-private partnership with FDA. Immuno-oncology play Arch Oncology Inc....
...Rahman stepped down as CSO of mAb developer CytoDyn Inc. (OTCQX:CYDY). BC Staff Tessera Therapeutics Inc. Syncona Ltd. Juvenescence Ltd. Medable Inc. Arch Oncology Inc. Mission...

...financing co-led by new investors Vesalius BioCapital III and BioMedPartners, with participation from all existing investors. Arch Oncology Inc....
...served as general counsel and chief compliance officer. BC Staff Abbisko Therapeutics Co. Ltd. Ziopharm Oncology Inc. Imara Inc. Inivata Ltd. Arch Oncology Inc. Topas...

...is presenting its first-in-human clinical trial design for AK117.Arch Oncology Inc....

...is presenting its first-in-human clinical trial design for AK117.Arch Oncology Inc....

...thinks FSI-189 won’t show single-agent activity in cancer, but could be used in combination regimens. Arch Oncology Inc....
...IgG1 mAb rituximab, which targets B cell cancers. Innovent has not disclosed its strategy. 3) Arch Oncology Inc....
...the clinic have made it clear that tackling the target’s toxicity will be their priority. Arch Oncology Inc....

...VP, head of nucleic acid therapies, external innovation at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Cancer company Arch Oncology Inc....
...was president and CMO of Furiex Pharmaceuticals Inc., which Amgen Inc. (NASDAQ:AMGN) acquired in 2014. BioCentury Staff Arch Oncology Inc. Cerevel...

...which is in a Phase I trial to treat solid tumors. President and CEO of Arch Oncology Inc....
...in 2016 (see "Tioma's Broad Basket" ). Chris Lieu, Staff Writer CD47 Signal regulatory protein alpha (SIRPA) (CD172a) (SHPS-1) AO-176 Arch Oncology Inc....

...the Institute of Stem Cell Biology and Regenerative Medicine at Stanford. Last week's announcement by Tioma...
...for achieving a better, less toxic way of performing transplants has enormous potential," Uger said. Tioma...
...PFE), New York, N.Y. Stanford University, Stanford, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Tioma...

...clinical program targeting CD47 . President and CEO John Donovan said the round should enable Tioma...
...Venture Fund and SR One co-led the round. RiverVest's John McKearn, who will serve as Tioma's...
...functionally diverse portfolio and we're certainly prepared to move forward with more than one product." Tioma's...